News

News

Preexisting Cardiovascular Conditions Nearly Double Heart Failure Risk Among Non-Hodgkin Lymphoma Survivors

Patients with non-Hodgkin lymphoma (NHL) that was treated with anthracycline-based chemotherapy have an increased risk of heart failure (HF), and the chances are even...

High Rates of Depression Resulting in Higher Health-Care Costs in Patients With Sickle Cell...

Depression is approximately five times more prevalent in patients with sickle cell disease (SCD) than in the general population, and it is significantly associated...

First CAR T-Cell Therapy for B-Cell Lymphoma Receives FDA Approval

The U.S. Food and Drug Administration (FDA) approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (or KTE-C19) for the treatment of adult...

Remembering Harold Roberts and Tessa Holyoake, CRISPR Researchers Awarded Albany Medical Center Prize, and...

Remembering Harold R. Roberts, MD Harold R. Roberts, MD, a leader in the field of thrombosis and hemostasis and two-time American Society of Hematology (ASH)...

ASH Announces New Executive Committee Members, ASH Members Visit Congress, and more

The Results Are In … ASH Announces 2018 Executive Committee Members ASH announced the election of four new members to its Executive Committee, the governing...

Manufacturer Suspends Trial of Fitusiran for Hemophilia After Patient Death

Alnylam Pharmaceuticals, Inc., suspended a phase II trial of its investigational RNA inhibitor fitusiran for patients with hemophilia after a patient with hemophilia A...

Brentuximab Vedotin Receives Priority Review for CTCL

The U.S. Food and Drug Administration (FDA) granted priority review to the anti-CD30 monoclonal antibody brentuximab vedotin (BV) for the treatment of cutaneous T-cell...
WIB_icon

Predicting the Risk and Severity of Cytokine Release Syndrome in Patients Receiving CAR T-Cell...

While treatment with CD19-directed chimeric antigen receptor (CAR) T cells has demonstrated impressive response rates of over 80% in select patients with B-cell malignancies,...
WIB_icon

Adding Rituximab to Corticosteroids and Cyclosporine A in Patients With cGVHD Improves ORR

Standard firstline treatment for chronic graft-versus-host disease (cGVHD) includes corticosteroids and cyclosporine A, but disease control often requires long-term immunosuppressive treatment, which impairs patients’...

Combination Antiplatelet Therapy Associated With Higher Mortality After ICH Than Single Antiplatelet Therapy

Antiplatelet therapy (APT) is associated with increased risk of intracerebral hemorrhage (ICH), though data about the association between APT use and mortality risk after...
Advertisement

Current Issue

November 2017, Volume 3, Issue 13

This issue features a behind-the-scenes look at the ASH annual meeting, bringing newly approved gene therapies to patients, and more.